^
Association details:
| Biomarker: | IGF1R expression |
|---|---|
| Cancer: | Thymoma |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Excerpt:
This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal....A statistically significantly shorter survival was observed in patients with a tumor positivity for p4E-BP1 (P < .001) and for IGF1R (P = .023)...
DOI:
10.1200/JCO.2017.74.4078
Trial ID:
